In focus
South Korea's Rznomics Secures European Orphan Drug Status for RNA-Editing Glioma Therapy
The European Commission has granted Orphan Medicinal Product Designation to Rznomics' RNA-editing gene therapy, RZ-001, for glioma treatment. This milestone strengthens the company's regulatory foundation across both European and U.S. markets.
Read the story